Paper33765296
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN. Drugs, 2021. Cited by 124 papers, by iCite.
Cite this record
ConductScience Library. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Papers, record 33765296. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33765296
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Idiopathic Pulmonary Fibrosis | Major topic |
| Indoles | Major topic |
| Lung Diseases, Interstitial | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Protein-Tyrosine Kinases | Major topic |
| Humans |
Source PubMed
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 33847978 | Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. | https://conductscience.org/library/papers/33847978 | PubMed |
| Erratum in | 34050918 | Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. | https://conductscience.org/library/papers/34050918 | PubMed |
References63
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26400368 | Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. | Respir Res | 2015 | https://conductscience.org/library/papers/26400368 | PubMed |
| 2 | 26063212 | Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis. | Drugs | 2015 | https://conductscience.org/library/papers/26063212 | PubMed |
| 3 | 31914963 | Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. | BMC Pulm Med | 2020 | https://conductscience.org/library/papers/31914963 | PubMed |
| 4 | 28861727 | Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient? | Drugs Aging | 2017 | https://conductscience.org/library/papers/28861727 | PubMed |
| 5 | 32010718 | Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. | ERJ Open Res | 2020 | https://conductscience.org/library/papers/32010718 | PubMed |
| 6 | 31566307 | Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31566307 | PubMed |
| 7 | 29490307 | Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. | Respiration | 2018 | https://conductscience.org/library/papers/29490307 | PubMed |
| 8 | 20813056 | Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. | Arthritis Res Ther | 2010 | https://conductscience.org/library/papers/20813056 | PubMed |
| 9 | 31016670 | Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/31016670 | PubMed |
| 10 | 26843176 | Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. | BMC Med | 2016 | https://conductscience.org/library/papers/26843176 | PubMed |
| 11 | 30971229 | Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials. | Respir Res | 2019 | https://conductscience.org/library/papers/30971229 | PubMed |
| 12 | 30814139 | Fibrosing interstitial lung diseases: knowns and unknowns. | Eur Respir Rev | 2019 | https://conductscience.org/library/papers/30814139 | PubMed |
| 13 | 31179001 | Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. | BMJ Open Respir Res | 2019 | https://conductscience.org/library/papers/31179001 | PubMed |
| 14 | 30224318 | Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. | Lancet Respir Med | 2019 | https://conductscience.org/library/papers/30224318 | PubMed |
| 15 | 27672117 | Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. | Thorax | 2017 | https://conductscience.org/library/papers/27672117 | PubMed |
| 16 | 33412120 | Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. | Lancet Respir Med | 2021 | https://conductscience.org/library/papers/33412120 | PubMed |
| 17 | 29946005 | Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. | Eur Respir J | 2018 | https://conductscience.org/library/papers/29946005 | PubMed |
| 18 | 32767182 | Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data. | Adv Ther | 2020 | https://conductscience.org/library/papers/32767182 | PubMed |
| 19 | 30665517 | Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. | Respir Med | 2019 | https://conductscience.org/library/papers/30665517 | PubMed |
| 20 | 29106740 | Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment. | J Clin Pharmacol | 2018 | https://conductscience.org/library/papers/29106740 | PubMed |
Cited by96
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 124 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42907787 | Nintedanib alleviates pulmonary inflammation and fibrosis in mice with silicosis. | BMC Pulm Med | 2026 | https://conductscience.org/library/papers/42907787 | PubMed |
| 42877793 | The unequal burden of interstitial lung disease mortality in older US adults: a 22-year analysis and projections to 2030. | Arch Med Sci | 2026 | https://conductscience.org/library/papers/42877793 | PubMed |
| 42820177 | Nintedanib-Associated Generalized Body Swelling in a Patient With Idiopathic Pulmonary Fibrosis: A Case Report. | Cureus | 2026 | https://conductscience.org/library/papers/42820177 | PubMed |
| 42786726 | Harmine Derivative H-2-104 Alleviates Echinococcus granulosus-Induced Pulmonary Fibrosis in Mice by Inhibiting Fibroblast Activation and Inducing DNA Damage. | J Immunol Res | 2026 | https://conductscience.org/library/papers/42786726 | PubMed |
| 42737450 | Association of PDGFRB, VEGFR2, and TGFB1 Gene Polymorphisms with Nintedanib Efficacy and Adverse Effects in Patients with Progressive Pulmonary Fibrosis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737450 | PubMed |
| 42696184 | Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment. | Curr Treat Options Oncol | 2026 | https://conductscience.org/library/papers/42696184 | PubMed |
| 42663780 | β-carboline derivative Z86 alleviates pulmonary fibrosis via suppressing TGF-β/Smad signaling. | Nat Prod Bioprospect | 2026 | https://conductscience.org/library/papers/42663780 | PubMed |
| 42656641 | Cryobiopsy at the dawn of fibrosis: unlocking early diagnosis and therapeutic windows. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42656641 | PubMed |
| 42650804 | In Vitro Assessment of Nintedanib in Keratoconus Corneal Stromal Microenvironment. | Biomolecules | 2026 | https://conductscience.org/library/papers/42650804 | PubMed |
| 42645433 | A CSF-1R Ig4-5 Domain-Targeting Antibody for the Treatment of Idiopathic Pulmonary Fibrosis. | Antibodies (Basel) | 2026 | https://conductscience.org/library/papers/42645433 | PubMed |
| 42644872 | Interstitial Lung Disease in the United States: CDC Mortality Trends (1999-2024). | Adv Respir Med | 2026 | https://conductscience.org/library/papers/42644872 | PubMed |
| 42509443 | Pirfenidone combined with nintedanib in connective tissue disease - associated interstitial lung disease with radiologic progression during antifibrotic monotherapy: A case series. | Clin Rheumatol | 2026 | https://conductscience.org/library/papers/42509443 | PubMed |
| 42334622 | Salvinorin A Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting M2 Macrophage Polarization and Macrophage-to-Myofibroblast Transition. | Lung | 2026 | https://conductscience.org/library/papers/42334622 | PubMed |
| 42297840 | Network-informed multi-trait genomic analysis decodes the shared genetic architecture and therapeutic landscape of pelvic floor disorders. | NPJ Aging | 2026 | https://conductscience.org/library/papers/42297840 | PubMed |
| 42115887 | Comparative efficacy and safety of monotherapy and combination pharmacotherapies for idiopathic pulmonary fibrosis: a network meta-analysis of randomized controlled trials. | BMC Pulm Med | 2026 | https://conductscience.org/library/papers/42115887 | PubMed |
| 42112343 | Kangxianhuanji formula and its component rutin ameliorate acute exacerbation of idiopathic pulmonary fibrosis by targeting GLUT1 to suppress HIF-1α-mediated glycolysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42112343 | PubMed |
| 42039347 | Nintedanib combined with anticoagulant therapy in advanced lung cancer complicated with pulmonary fibrosis and pulmonary embolism: two case reports and clinical decision-making analysis. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42039347 | PubMed |
| 41750384 | Effects of Nintedanib on Orofacial Fibroblasts and Myoblasts. | Biomolecules | 2026 | https://conductscience.org/library/papers/41750384 | PubMed |
| 41731806 | Correlation between red cell distribution width to total calcium ratio and in-hospital mortality in patients with non-idiopathic pulmonary fibrosis interstitial lung diseases: A retrospective cohort study from the MIMIC-IV database. | Medicine (Baltimore) | 2026 | https://conductscience.org/library/papers/41731806 | PubMed |
| 41694584 | Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/41694584 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABCB1 | 5243 | PubTator's text mining | https://conductscience.org/library/genes/5243 | NCBI Gene |
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 | NCBI Gene |
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| PDGFRB | 5159 | PubTator's text mining | https://conductscience.org/library/genes/5159 | NCBI Gene |
| PGP | 283871 | PubTator's text mining | https://conductscience.org/library/genes/283871 | NCBI Gene |
| TGFB1 | 7040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
| TIMP2 | 7077 | PubTator's text mining | https://conductscience.org/library/genes/7077 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33765296
GET https://conductscience.org/api/papers/v1/33765296/references?page=2